Major outcomes after HCT for all patients enrolled. Cumulative incidence frequencies of acute GVHD grades 2 to 4 and 3 to 4 (A), and of chronic GVHD according to NIH criteria (B). Cumulative incidence frequencies of NRM (C) and myeloma relapse or progression (D). Kaplan-Meier estimates of PFS (E) and OS (F). Panels C-F are organized according to patients treated for newly diagnosed high-risk myeloma (n = 24; solid lines) or failed prior therapy (n = 7; dashed lines) as further described in “Methods.” Outcomes shown in panels C-F are based on intention to treat and counted from the time of autoHCT.